Glavinskaia T A, Pavlova L T, Dorofeĭchuk V G
Vestn Dermatol Venerol. 1990(3):21-5.
Lysozyme was administered to 57 patients with lupus erythematosus (LE) for 10 days according to 4 schemes: Group 1 (n = 10)--30 mg of lysozyme 3 times a day sublingually; Group 2 (n = 10)--100 mg daily i.m.; Group 3 (n = 10)--100 mg twice a day i.m.; Group 4 (n = 27)--100 mg 3 times a day i.m. After a course of lysozyme therapy patients with discoid and disseminated LE were prescribed delagil, those with systemic LE were administered corticosteroid hormones in moderate doses or presocyl. The treatment was well tolerated, only 2 (3.5%) patients developed toxicoderma. The results evidence that lysozyme efficacy is not inferior to that of levamisole but this agent is better tolerated. Clinical and paraclinical efficacy was higher in Groups 1 and 4; cellular, humoral, and local immunity parameters, as well as the characteristics reflecting the inflammatory processes evidence positive changes developing as a result of lysozyme therapy, these changes persisting in the majority of cases during further combined treatment. Therapy with low doses of lysozyme is indicated for patients with the immune status disorders mainly. If changes in the nonspecific resistance predominate, the scheme used in Group 4 is advisable.
根据4种方案，对57例红斑狼疮（LE）患者给予溶菌酶治疗10天：第1组（n = 10）——每天3次舌下含服30 mg溶菌酶；第2组（n = 10）——每天肌肉注射100 mg；第3组（n = 10）——每天肌肉注射2次，每次100 mg；第4组（n = 27）——每天肌肉注射3次，每次100 mg。溶菌酶治疗一疗程后，盘状和播散性LE患者给予地拉吉，系统性LE患者给予中等剂量的皮质类固醇激素或普索西尔。治疗耐受性良好，仅2例（3.5%）患者出现药疹。结果表明，溶菌酶的疗效不低于左旋咪唑，但该药物耐受性更好。第1组和第4组的临床和副临床疗效更高；细胞、体液和局部免疫参数以及反映炎症过程的特征表明，溶菌酶治疗后出现了积极变化，这些变化在大多数情况下在进一步联合治疗期间持续存在。低剂量溶菌酶治疗主要适用于免疫状态紊乱的患者。如果非特异性抵抗力变化占主导，第4组使用的方案是可取的。
